3 results
Primary objective:Determine the short- and long-term safety and tolerability of single and multiple doses of NI006 in subjects with ATTR-CM by evaluating adverse events (AE) and serious adverse events (SAE) and changes in laboratory parameters (…
Primary efficacy objectives:To evaluate the efficacy of lenabasum 20 mg twice per day (BID) compared to placebo in the treatment of cystic fibrosis (CF) by assessing the rate of pulmonary exacerbations (PEx) using primary definition of PEx.Secondary…
Primary Efficacy Objective:To evaluate the efficacy of lenabasum compared to placebo in the treatment of SSc by assessing the American College of Rheumatology (ACR) Provisional Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS)…